Publication | Open Access

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

UrologyOncologyGenitourinary CancerMedicineClinical TrialsPharmacotherapyCancer TreatmentProstatic DiseasePharmacology